B O O K - American College of Rheumatology

monday
Physiology, University Hospital Zurich, Switzerland, 2 Department
of Internal Medicine 3 , University Erlangen-Nuremberg,
Germany, 3 Laboratory of Neurosciences, National Institute on
Aging Intramural Research Program, Baltimore, MD
3:15 PM
673. Myofibroblast Specific Gene Expression Signature in
Systemic Sclerosis, More Than TGF-beta Induced Activation.
Giuseppina Abignano 2 , Heidi Hermes, Justin Gillespie, Sergio
A. Jimenez, Paul Emery and Francesco Del Galdo 1 , 1 Leeds,
2
University of Leeds
3:30 PM
674. Perturbed VEGF Signalling within the Pulmonary
Vasculature of a TGFβ Dependent Mouse Model of Systemic
Sclerosis.
Emma C. Derrett-Smith 2 , Audrey Dooley 2 , Reshma Baliga 1 ,
Adrian Hobbs 1 , Raymond MacAllister 1 , David Abraham 4 and
Christopher P. Denton 3 , 1 Centre for Clinical Pharmacology, Rayne
Institute, UCL, London, Canada, 2 Centre for Rheumatology and
Connective Tissue Diseases, Royal Free Campus, UCL Medical
School, London, 3 Royal Free Hospital, London, United Kingdom,
4University College London, London, United Kingdom
3:45 PM
675. The IL13/IL4RA/CCL2 Pathway Drives Sclerodermatous
Graft Versus Host Disease in Mice and Correlates with Disease
Activity in Scleroderma Patients.
Antonios O. Aliprantis 4 , Matthew Greenblatt 3 , Jennifer Sargent 2 ,
Giuseppina Farina 6 , Kelly Tsang 3 , Robert A. Lafyatis 1 , Michael
Whitfield 2 and Laurie Glimcher 5 , 1 Boston University School of
Medicine, Arlington, MA, 2 Department of Genetics, Dartmouth
Medical School, 3 Department of Immunology and Infectious
Diseases, Harvard School of Public Health, 4 Department of
Medicine, Division of Rheumatology, Allergy and Immunology,
Brigham and Women’s Hospital and Harvard Medical School and
Department of Immunology and Infectious Diseases, Harvard
School of Public Health, Boston, MA, 5 Department of Medicine,
Division of Rheumatology, Allergy and Immunology, Brigham and
Women’s Hospital and Harvard Medical School and Department
of Immunology and Infectious Diseases, Harvard School of Public
Health, 6 Rheumatology Section, Boston University School of
Medicine
United Kingdom, 2 Addenbrooke’s Hospital, 3 Charles University,
4
Immunologie-Zentrum Zürich, Zurich, Switzerland, 5 Maastricht
University Medical Center, Maastricht, The Netherlands,
6
Maastricht University Medical Center, 7 Nuffield Orthopaedic
Centre, Oxford, United Kingdom, 8 Royal Adelaide Hospital,
Adelaide, Australia, 9 University Hospital of Skane and Lund
University, Lund, 10 University Hospital of Skane and Lund
University, 11 University of Birmingham, Birmingham, United
Kingdom
2:45 PM
677. Increased Circulating Osteoclast Precursors and Lesional
Osteoclast-Like Multinucleated Giant Cells in the Lung of
Patients with Wegener’s Granulomatosis.
Jin Kyun Park 1 , Frederic Askin 2 , Antony Rosen 3 and Stuart M.
Levine 1 , 1 Johns Hopkins University, Baltimore, MD, 2 Johns
Hopkins University, 3 The Johns Hopkins University, Baltimore,
MD
3:00 PM
678. Protocolised Versus Non-Protocolised Rituximab
Treatment for Refractory ANCA-Associated Vasculitis.
Rachel B. Jones 1 , Rona Smith 2 , Mary-Jane Guerry 2 , Simona
Laurino 2 , Fausta Catapano 2 , Afzal Chaudhry 2 and David R. W.
Jayne 1 , 1 Addenbrooke’s Hospital, Cambridge, United Kingdom,
2
Addenbrooke’s Hospital
3:15 PM
679. Xenografted Nasal Mucosa from Wegener’s
Granulomatosis Patients Induces Destruction of Human
Cartilage in Immunodeficient Mice.
Nina Kesel 2 , Dorothee Köhler 2 , Martin Laudien 5 , Konstanze Holl-
Ulrich 3 , Astrid Jüngel 1 , Michel Neidhart 1 , Steffen Gay 1 , Renate
E. Gay 1 , Elena Csernok 6 , Wolfgang L. Gross 6 , Udo Schumacher 4
and Sebastian Ullrich 4 , 1 Center of Experimental Rheumatology,
University Hospital Zurich, Switzerland, 2 Dept. of Anatomy II:
Experimental Morphology, University Medical Center Hamburg,
Hamburg, Germany, 3 Dept. of Pathology, University Hospital
of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany,
4
University Medical Center Hamburg, 5University of Kiel, Dept.
of Otorhinolaryngology, Head and Neck Surgery, Kiel, Germany,
6
University of Lübeck, Dept. For Rheumatology, Vasculitis Center
UKSH & Clinical Center Bad Bramstedt, Lübeck, Germany
A314
ANCA-associated Vasculitis I
Moderators: Simon Carette, MD; Toronto Western Hospital;
Toronto, ON, Canada
Loic P. Guillevin, MD; Hôpital Cochin-Paris Université; Paris,
France
2:30 PM
676. Two Year Follow-Up Results from a Randomised Trial of
Rituximab Versus Cyclophosphamide for ‘Generalized’ ANCA-
Associated Vasculitis: RITUXVAS.
Rachel B. Jones 1 , Jan Willem Cohen Tervaert 5 , Thomas Hauser 4 ,
Raashid Luqmani 7 , Matthew D. Morgan 11 , Chen Au Peh 8 , Caroline
O. Savage 11 , Mårten Segelmark 9 , Vladimir Tesar 3 , Pieter van
Paassen 6 , Dorothy Walsh2, Michael Walsh 2 , Kerstin Westman 10
and David R. W. Jayne 1 , 1 Addenbrooke’s Hospital, Cambridge,
3:30 PM
680. Rituximab for Remission Induction and Maintenance
in ANCA-Associated Vasculitis: A Single-Center Ten-Year
Experience in 108 Patients.
Rodrigo Cartin-Ceba 3 , Jason Golbin 1 , Karina A. Keogh 3 , Tobias
Peikert 3 , Fernando C. Fervenza 3 , Steven R. Ytterberg 2 and Ulrich
Specks 3 , 1 Long Island Lung Center, 2 Mayo Clinic, Rochester, MN,
3
Mayo Clinic
3:45 PM
681. Hsp60 Proteolysis by Proteinase 3 Induces Neutrophil
Degranulation: Implications for Amplification of Injury in
Wegener’s Granulomatosis.
Shinji Sato 4 , Jin Kyun Park 1 , Frederic Askin 3 , Antony Rosen 2
and Stuart M. Levine 1 , 1 Johns Hopkins University, Baltimore,
MD, 2 The Johns Hopkins University, Baltimore, MD, 3 The Johns
Hopkins University, 4 Tokai University, Kamakura, Japan
44
2010 Program Book